September 28, 2016
Bloomberg BNA
On September 27, 2016, a Maryland district court ruled in favor of Finnegan client Elan Pharmaceuticals, stating that the company's study on muscle relaxant Skelaxin does not infringe a Classen Immunotherapies Inc. patent.
In 2001, the FDA approved Elan's abbreviated new drug application (ANDA) for Skelaxin, but later sought Elan's feedback on a proposal to change Skelaxin's label. Elan then conducted a clinical trial to analyze the effect of food on the absorption of metaxalone and submitted the results to the FDA to revise the label and to propose changes to the approval requirements for generic versions of the drug. Classen alleged that the study, the information that would be on Skelaxin's label, and Elan's activities related to filing for new patents as a result of what it learned infringed its patent.
In 2012, the district court granted summary judgment in favor of Elan under the "safe harbor" of the Hatch-Waxman Act, which exempts generic drug makers from liability for infringing activity that's "reasonably related to the development and submission of information" to the FDA. The Federal Circuit applies this to brand name makers as well. Thus, the Federal Circuit affirmed this decision, but remanded the case only because the original district court opinion didn't say enough about whether some of Elan's activities met the "reasonably related" characterization. On remand, the court agreed with the Federal Circuit.
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.